Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 add-on therapy in poorly controlled asthma
NL-OMON41186Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing NVA237 add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Trough FEV1 at Week 26. Planned start Jan 2014; status: withdrawn.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON41186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41186.